Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 999-1005, February 15, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishimura, Y.
Right arrow Articles by Watanabe, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishimura, Y.
Right arrow Articles by Watanabe, T.

Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen1

Yushi Nishimura, Masatoshi Yokoyama, Kazuo Araki, Ryuzo Ueda, Akira Kudo and Takeshi Watanabe2

Department of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka [Y. N., M. Y., K. A., A. K., T. W.,] and Laboratory of Chemotherapy, Aichi Cancer Research Institute, Nagoya [R. U.], Japan

A human-mouse chimeric antibody constructed in the present study was specific for a human tumor-associated antigen, common acute lymphocytic leukemia antigen. The antibody consisted of human heavy and light chain constant domains ({gamma}1 and k type) and mouse heavy and light chain variable domains, which were derived from human plasma cell leukemia line (ARH77) and mouse hybridoma cells (NL-1) specific for common acute lymphocytic leukemia antigen, respectively. The artificially fused immunoglobulin molecules were produced in mouse myeloma cells, X63Ag8.653 which were transformed with the chimeric heavy and light chain genes formed by joining the corresponding gene segments in vitro at the J-C introns. The human heavy chain enhancer element was ligated to the chimeric heavy and light chain genes, and this enhancer appeared to be obligatory for the efficient production of the chimeric antibody molecules. The stably transformed cells secreted the chimeric antibody, which specifically bound a common acute lymphocytic leukemia antigen expressing cell line. The amount of the chimeric antibody produced (10–30 µg/ml in the serum-free medium) was comparable to that made by murine hybridoma line, NL-1. The molecular weight of the chimeric heavy chain molecules was reduced from 54,000 to 50,000 upon treatment with tunicamycin, suggesting that the peptide was normally glycosylated in the transformants. The chimeric antibody exhibited complement-dependent cytotoxicity, in which glycosylation is thought to be indispensable. The antibody also mediated antibody-dependent cell-mediated cytotoxicity to the human target cells. The antibody-dependent cell-mediated cytotoxicity activity of the chimeric antibody was twice that of the murine NL-1 monoclonal antibody when human peripheral blood mononuclear cells were used as effectors.

1 This work was supported by a grant-in-aid for cancer research from the Ministry of Education, Science, and Culture of Japan.

2 To whom requests for reprints should be addressed, at Medical Institute of Bioregulation, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812, Japan.

Received 7/ 2/86. Revised 10/20/86. Accepted 11/18/86.




This article has been cited by other articles:


Home page
DevelopmentHome page
T. Fujii, F. Nakao, Y. Shibata, G. Shioi, E. Kodama, H. Fujisawa, and S. Takagi
Caenorhabditis elegans PlexinA, PLX-1, interacts with transmembrane semaphorins and regulates epidermal morphogenesis
Development, January 5, 2002; 129(9): 2053 - 2063.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
M. Shimizu, Y. Murakami, F. Suto, and H. Fujisawa
Determination of Cell Adhesion Sites of Neuropilin-1
J. Cell Biol., March 20, 2000; 148(6): 1283 - 1294.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. S. Graves, S. C. Goshorn, D. M. Stone, D. B. Axworthy, J. M. Reno, B. Bottino, S. Searle, A. Henry, J. Pedersen, A. R. Rees, et al.
Molecular Modeling and Preclinical Evaluation of the Humanized NR-LU-13 Antibody
Clin. Cancer Res., April 1, 1999; 5(4): 899 - 908.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Yoshihara, M. Kawasaki, A. Tamada, H. Fujita, H. Hayashi, H. Kagamiyama, and K. Mori
OCAM: A New Member of the Neural Cell Adhesion Molecule Family Related to Zone-to-Zone Projection of Olfactory and Vomeronasal Axons
J. Neurosci., August 1, 1997; 17(15): 5830 - 5842.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Mizuno, Y. Yoshihara, J. Inazawa, H. Kagamiyama, and K. Mori
cDNA Cloning and Chromosomal Localization of the Human Telencephalin and Its Distinctive Interaction with Lymphocyte Function-associated Antigen-1
J. Biol. Chem., January 10, 1997; 272(2): 1156 - 1163.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.